Onconetix, INC S-1 registration statements

Onconetix, Inc. has filed an S-1 registration statement for the resale of up to 100 million shares of common stock by selling stockholders, highlighting significant financial challenges and a substantial accumulated deficit.

Onconetix, Inc. has filed an amendment to its Form S-1 registration statement, primarily to include an exhibit containing a legal opinion regarding the securities being registered.

Onconetix, Inc. is registering nearly 30 million shares for resale by institutional investors, while simultaneously facing substantial doubt about its ability to continue as a going concern and abandoning its ENTADFI product.

Onconetix, a commercial-stage biotechnology company, filed an S-1 registration statement for the resale of 22,071,891 shares of common stock by selling stockholders, following recent Series D and E PIPE financings and ongoing financial challenges.

Onconetix, a commercial-stage biotech, filed an S-1 to register 5.1 million common shares for resale by Keystone Capital Partners under an existing equity line of credit, while facing significant financial challenges and abandoning a key product.

Onconetix, Inc. has filed an amendment to its Form S-1 registration statement to register the potential sale of up to 50,000,000 shares of common stock through an equity line of credit with Keystone Capital Partners, LLC, aiming to raise up to $25 million.

Onconetix, Inc. has filed an S-1 registration statement to allow for the potential sale of up to 50 million shares of common stock by Keystone Capital Partners, LLC through an equity line of credit.

Onconetix, Inc. has filed an amendment to its S-1 registration statement, disclosing a new $25 million equity line of credit agreement with Keystone Capital Partners, LLC.

Onconetix, Inc. has filed an amendment to its registration statement to facilitate the potential sale of up to 6,250,000 shares of common stock through an equity line of credit with Keystone Capital Partners, LLC.

Onconetix enters into a common stock purchase agreement with Keystone Capital Partners for up to $25 million, concurrently filing an amendment to its S-1 registration statement for the resale of up to 6,250,000 shares.

Onconetix, Inc. has filed an amendment to its Form S-1 registration statement, primarily to include an updated exhibit related to the legality of the securities being registered.

Onconetix, Inc. has filed a registration statement for the resale of up to 10,586,556 shares of common stock by selling stockholders, following recent PIPE financings, warrant exercises, and a reverse stock split.

Onconetix, Inc. has filed a registration statement for the potential sale of up to 6,250,000 shares of common stock through an equity line of credit (ELOC) with Keystone Capital Partners, aiming to raise up to $25 million.

Onconetix files an amendment to its registration statement for the resale of common stock, outlining its financial position, strategic shifts, and associated risks.

Onconetix, a commercial-stage biotechnology company, has filed an amendment to its registration statement for the resale of 7,828,812 shares of its common stock by selling stockholders.

Onconetix, a commercial-stage biotech company, files an amendment to its Form S-1 registration statement to allow selling stockholders to resell 7,828,812 shares of common stock.

Onconetix, Inc. has filed a registration statement for the resale of 5,121,601 shares of its common stock by selling stockholders.